- Krane RJ, Goldstein L, Saenz de Tejada I (1989). Impotence. N Engl J Med., 321, 1648–1659.
- Feldman HA, Goldstein I, Hatzchristou DG, Krane RJ, McKinlay JB (1994). Impotence and its medical and social correlates: results of the Massachusetts Male Aging Study. J Urol., 151, 54–61.
- Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN (1994). Total cholesterol and high density lipoprotein cholesterol as im-portant predictors of erectile dysfunction. Am. J. Epidemiol., 140, 930–937.
- Virag R, Bouilly P, Frydman D (1985). Is im-potence an arterial disorder? A study of ar-terial risk factors in 440 impotent men. Lancet, i, 181–184.
- Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I (1998). Mechanisms of ischemia-induced cavernosal smooth muscle relaxation in a rabbit model of vasculogenic erectile dys-function. J. Urol., 160, 2216–2222.
- Azadzoi KM, Saenz de Tejada I (1991). Hypercholesterolemia impairs endothe-lium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J. Urol., 146, 238–240.
- Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen P-O, Carson CC (1994). Experi-mental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle dysfunc-tion. J. Urol., 151, 198–205.
- Shimokawa H (1999). Primary endothelial dysfunction: atherosclerosis. J. Mol. Cell. Cardiol., 31, 23–37.
- Bruckert E, Giral P. Heshmati HM, Turpin G (1996). Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J. Clin. Pharm. Ther., 21, 89–94.
- Pedersen TR, Faergeman O. (1999). Simvastatin seems unlikely to cause impo-tence. BMJ, 318, 192.
- O'Driscoll G, Green D, Taylor RR (1997). Simvastatin, an HMG-coenzyme A reductase inhibitors, improves endothelial function within 1 month. Circulation, 95, 1126–1131.
- Figueras A, Castel JM, LaPorte JR, Capella D (1993). Gemfibrozil-induced impotence. Ann. Pharmacother., 27, 982.
- Blane GF (1987). Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am. J. Med., 83 (Suppl 5B), 26–36.
- Rubins HB, Robins SJ, Collins D, et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veteran Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 341, 410–418.
Current Medical Research and Opinion
Volume 16, 2000 - Issue sup1